Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 22 2022 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop novel therapeutics that target specific viral
diseases, today announced that the Company will participate in a
fireside chat at Chardan’s 6th Annual Genetic Medicines Conference
taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET.
Presenters: William Collier, President &
Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Offer;
Dr. Gaston Picchio, Chief Development Officer; and David Hastings,
Chief Financial Officer
A live webcast of the fireside chat can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com. An archived replay of the webcast will be
available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are
developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1
inhibitor, and oral RNA destabilizer that we intend to combine to
provide a functional cure for patients with chronic HBV by
suppressing viral replication, reducing surface antigen and
reawakening the immune system. We believe our lead compound,
AB-729, is the only RNAi therapeutic with evidence of immune
re-awakening. It is currently being evaluated in multiple phase 2
clinical trials. We also have an ongoing drug discovery and
development program directed to identifying novel, orally active
agents for treating coronavirus (including SARS-CoV-2). In
addition, we are exploring oncology applications for our internal
PD-L1 portfolio. For more information, visit
www.arbutusbio.com.
Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.com
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024